Quick Answer
Acumen Pharmaceuticals, Inc. reported Net Income of -$121.33 million for fiscal year 2025.
Acumen Pharmaceuticals, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$121.33M | -18.6% |
| 2024 | -$102.33M | -95.4% |
| 2023 | -$52.37M | -22.2% |
| 2022 | -$42.86M | +57.4% |
| 2021 | -$100.61M | -1273.5% |
| 2020 | -$7.33M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$26.45M | +11.1% | +35.4% |
| June 30, 2025 | -$40.95M | -99.4% | -42.2% |
| March 31, 2025 | -$28.80M | -93.6% | +3.3% |
| September 30, 2024 | -$29.77M | -129.7% | -44.9% |
| June 30, 2024 | -$20.54M | -76.9% | -38.1% |
| March 31, 2024 | -$14.87M | -31.5% | -14.8% |
| September 30, 2023 | -$12.96M | -21.0% | -11.6% |
| June 30, 2023 | -$11.61M | -14.4% | -2.7% |
- Acumen Pharmaceuticals, Inc. showed a decrease of -18.6% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, Acumen Pharmaceuticals, Inc.’s net income has declined by 1556.5% (from -$7.33 million to -$121.33 million).
- The most recent figure is from Acumen Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: